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Abstract
Background: Little is known about the role European patient organisations play in the process of deciding on
reimbursement for medicines. Therefore we explore the current role of patient organisations in the process of
reimbursement for medicines in Western Europe. We focus in particular on collaboration between patient
organisations and the pharmaceutical industry in this respect.
Methods: Sixty-eight patient organisations representing seven medical conditions, from ten Western European
countries, were asked to participate in the study. The participating organisations reported their experiences in a
web-based questionnaire.
Results: Twenty-one patient organisations completed the questionnaire (response rate: 31%), of which ten (47.6%)
demanded reimbursement for medicines. Organisations demanding reimbursement were larger than those not
demanding reimbursement. The main aim of these organisations was to create better accessibility of medicines for
patients. Most organisations limited themselves to single actions. Only two engaged in multiple actions. Almost all
organisations had general policies on cooperation with the pharmaceutical industry, with autonomy as the key
feature. The patient organisations said they were reasonably successful and almost always satisfied with their own
role in the reimbursement process.
Conclusion: Our study has found that the role of European patient organisations in the reimbursement process
still seems limited, especially for small patient organisations.
Background
Often, advanced and expensive medicines are not fully
reimbursed. Stakeholders such as patient organisations
may call for better reimbursement conditions [1,2]. The
decision-making process regarding reimbursement dif-
fers between European countries. Differences also exist
in the possibilities available to patient organisations to
influence these decisions, depending on the reimburse-
ment system of the country, the position of the patient
organisation and the level of professionalization within
the organisation [3]. Consequently, there are variations
in reimbursement for medication between European
countries. The Alzheimer associations, for example,
state that access by European citizens to existing anti-
dementia drugs is unequal. While in some countries,
like Ireland and Sweden, all Alzheimer medicines are
reimbursed without restrictions, other countries, such as
the Netherlands and the UK exclude some medicines or
treatment groups [4].
Patients and their representatives (e.g. patient organisa-
tions) are becoming increasingly important in creating
access to healthcare and medicines. Patient organisations
may act as an advocate for the patients they represent in
the decision-making process regarding reimbursement for
medicines. Since the authorities do not provide enough
financial support for patient organisations to perform their
activities, many organisations receive funding from the
pharmaceutical industry [5,6]. The funding of patient
organisations (and their relationship with the pharmaceu-
tical industry) is frequently the subject of debate [5-13].
However, little is known about the role patient organisa-
tions occupy concerning the reimbursement of medicines.
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organisations to ask NIVEL for an exploratory study in
this field, in order to learn from other organisations’
experiences. The aim of the present paper is therefore to
explore the current role of patient organisations in the
process of reimbursement of medicines in Western Eur-
ope. We focus in particular on the cooperation between
patient organisations and the pharmaceutical industry,
regarding the process of reimbursement for medicines.
This collaboration with the industry remains complex,
since conflicts of interest can appear when patient organi-
sations do not maintain their independence [7,8]. The
autonomy of patient organisations is jeopardised by the
fact that they would be unable to function without finan-
cial aid from the industry. For instance, there is a risk that
patient organisations could be used to sell the medicines
supported by the industry [9]. At the same time, patient
organisations and the industry share a common interest in
creating access to specific treatments and medicines.
In sum, this paper’s research questions are:
1. What is the role of European patient organisations
in the process of reimbursement for medicines?
2. How successful are patient organisations in achiev-
ing their goals within this process?
3. How do patient organisations define their relation-
ship vis à vis the pharmaceutical industry, regarding the
reimbursement process of medicines?
The research was carried out by NIVEL (Netherlands
I n s t i t u t ef o rH e a l t hS e r v i c e sR e s e a r c h )a tt h er e q u e s to f
a steering committee, consisting of several Dutch patient
organisations, and was funded by Glaxo Smith Kline
(GSK). The steering committee of the 2007 meeting
consisted of representatives from the Dutch Cancer Fed-
eration, the Netherlands Patient and Consumer Federa-
tion, Diabetes Union Netherlands and the Asthma
Foundation. The committee was chaired by a former
Dutch minister of Public Health (Borst). GSK did not
participate in the design and reporting of the study,
while the steering committee had an advising role in the
design and reporting of the study. Confidentially was no
issue, because the NIVEL-institute has the statutory
obligation to publicly publish the results of its work.
Furthermore, in the research contract independence and
freedom of publication was secured.
Methods
Sixty-eight patient organisations in ten European coun-
tries were asked to fill in a web-based questionnaire.
The countries included were: Belgium, Denmark, Ger-
many, Finland, France, Ireland, the Netherlands, the
United Kingdom, Sweden, and Switzerland. These coun-
tries were chosen because they have a similar ‘medicine
culture’, in contrast to for example southern European
countries [14] and therefore more learning experiences
for the Dutch situation could be expected. Moreover,
language was an issue. The questionnaire was developed
in four languages (Dutch, English, French and German)
and from the selected countries we could expect that
the representatives could read and understand one of
these four languages.
For each country a maximum of seven organisations
was contacted. We chose to contact four large categori-
cal patient organisations because we hypothesized that
to undertake actions a certain volume may be necessary
and because these organisations may have more power
in terms of money and personnel to influence reimbur-
sement processes. The following four diseases were
selected: diabetes, cardio-vascular disease, asthma (and
allergy), multiple sclerosis. Since innovative medicines
are developed for rare diseases, we decided to select a
patient organisation for a rare disease as well. The
choice for Addison Cushing was based upon a discus-
sion with a senior researcher who knows the field of
rare diseases. Finally two patient organisations were cho-
sen for recently registered medication. Selection was
based upon information of the websites of EMEA http://
www.ema.europa.eu, the Dutch Medication Evaluation
Board and through websites of patient organisations. In
the end, Parkinson’s disease and ADHD were selected.
Through searching the internet we obtained the
addresses of the patient organisations we wanted to
invite. Patient organisations were approached by e-mail
and asked whether or not they wanted to participate in
the study. In addition, we asked who was most eligible to
fill out the questionnaire. We explicitly mentioned that
the study was subsidized by GSK and that a steering
committee of patient organisations had asked us to per-
form the study. The mail was sent out in Dutch, English,
French or German. Respondents were asked to fill out a
web-based questionnaire. After agreement upon partici-
pation the person who was mentioned as the respondent
received an e-mail with a link to this questionnaire. The
questionnaire was available for a one-month period. In
order to increase the response rate all non-responding
organisations were reminded three times. We considered
three reminders to be still acceptable, without becoming
too harassing.
We developed the questionnaire based on literature
about patient organisations and the reimbursement pro-
cess and on advices of members of the steering commit-
tee, existing of representatives of patient organisations.
Since our study was the first specifically on this subject,
it was hard to construct structured questionnaires with
relevant answer categories. Therefore, we decided to use
aq u e s t i o n n a i r ew i t ho p e n - e nded questions. The ques-
tionnaire was reviewed by a number of fellow researchers
with relevant experience as well as by a representative of
a Dutch patient organisation with an interest in research.
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tics of the organisation, actions taken to obtain reimbur-
sement, cooperation with other organisations and parties,
evaluating the role of the organisation, recommendations
for other patient organisations, and the policy of the
organisation. If the organisations did not take action for
the reimbursement process of a medicine, they were
asked if they had ever considered doing so, whether their
cooperation was requested by other organisations and
why action was not taken (see table 1 for the research
q u e s t i o n s ) .T oa v o i db i a si nsummarizing and reporting
the results of the questionnaire all authors looked at the
outcomes independently; JN summarized the findings,
LvD and RF separately controlled the findings and
reported results. Ethical approval for this type of research
is not necessary according to Dutch law. Analyses were
descriptive. We distinguished between patient organisa-
tions that took action for the reimbursement of medi-
cines and those that did not.
Results
Representatives of twenty-one patient organisations,
representing seven medical conditions and eight coun-
tries, reported their experiences in the web-based ques-
tionnaire (response rate: 31%). Two other patient
organisations did not complete the questionnaire. No
German or British patient organisations participated in
the study. Belgium (n = 5) and the Netherlands (n = 4)
had the highest response (see Table 2, 3).
The role of patient organisations in the reimbursement
process and their success
Eleven, mainly small-scale, independent organisations did
not take action for the reimbursement of medicines (see
table 4 for their characteristics). These organisations never
considered starting a reimbursement process and did not
cooperate with the pharmaceutical industry. Moreover,
they were not asked by others to participate in actions to
obtain reimbursement. Reasons for not taking action for
the reimbursement of medicines were not given.
Ten large-scale organisations demanded reimburse-
ment. A number of these were part of a European and
international network. A network consisted for example
of Heart and vascular disease patient organisations in
seven different countries. The ten organisations repre-
sented several medical conditions. Reimbursement was
requested for a variety of drugs, such as statins, clopido-
grel, asthma-inhalers and methylphenidate. The initiative
to demand reimbursement always stemmed from the
organisations themselves. Respondents reported that the
pharmaceutical industry did not approach the patient
organisations to take action regarding reimbursement of
medicines. Patient organisations cited the following rea-
sons for requesting reimbursement: to create access to a
medicine, to seek agreement on reimbursement of a
higher dose, to facilitate proper treatment and to reim-
burse a medicine that is frequently prescribed by doctors.
Most of these organisations limited themselves to single
activities: writing one or more letters or participating in a
Table 1 Questions in the on-line questionnaire
- Has your organisation ever taken action about the pricing/and or the payment allowance for a drug?
(e.g. by contacting other organisations or groups, submitting complaints, taking legal steps)
- In the case of which drug(s) did your organisation take action?
- For which reason(s) did your organisation take action?
- What form did the action(s) take?
(please also refer to the authorities or bodies at which the action was aimed)
- What did your organisation wish to achieve with the action?
- Did your organisation achieve its goal?
- Did your organisation take action alone or jointly with others?
- Which action(s) did your organisation undertake with others?
- With whom did your organisation undertake the action(s)?
- Who took the initiative to act jointly?
- With hindsight, how does your organisation evaluate its role in the process (according to level of satisfaction)? Please give your reasons for
the answer.
- Which recommendations would your organisation give to other patient organisations? (please indicate what you would advise and what you
would advise against)
- Does your organisation have a policy (protocol) on collaboration with the pharmaceutical industry? Please indicate the key points of your
organisation’s policy (or protocol).
So far your organisation has taken no action in respect of the pricing or payment allowance for drugs. In that case please answer the questions below.
- Has your organisation ever been approached with a view to taking action in respect of pricing and/or the payment allowance for drugs?
- Has your organisation ever considered taking action?
- By whom was your organisation approached?
- Why did you not take this up/take any action?
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the Netherlands) took multiple actions. They wrote let-
ters, invited the concerned parties for a consultation ses-
sion, contacted the media and funded research on the
living conditions of members (see Table 5). Half of the
organisations cooperated with others, for example with
other patient organisations, individual patients, medical
specialists or nurses and/or the pharmaceutical industry.
Patient organisations evaluated their actions as reason-
ably successful and were almost always satisfied with
them. We asked the patient organisations that took
action whether they had recommendations for other
organisations and if so what they would advise. The
results were ambiguous: some organisations recom-
mended cooperating with professionals and their organi-
sations while others advised against depending on other
organisations. Solid information facilities and a profes-
sional management for patient organisations were men-
tioned several times.
Policy and cooperation with the pharmaceutical industry
We looked at how patient organisations define their
relationship with the pharmaceutical industry regarding
the reimbursement of medicines, based on their policy.
Almost all patient organisations in our study had a pol-
icy of (potential) cooperation with the pharmaceutical
i n d u s t r y .U s u a l l y ,t h i sp o l i c y was formulated in general
Table 2 Patient organisations that participated
in the study
Responding patient organisations:
- Vlaamse Vereniging van Cushing Addison, Belgium
- Astma en Allergiekoepel, Belgium
- Vlaamse Diabetes Vereniging, Belgium
- Nationale Belgische Multiple Sclerose Liga, Belgium
- Belgian Heart League, Belgium
- Dansk Parkinsonforening, Denmark
- Heart Foundation, Denmark
- Finnish Heart Association, Finland
- Allergia-ja Astmaliitto, Finland
- HyperSupers TDAH (ADHD), France
- Diabetes Federation, Ireland
- Young Parkinson, Ireland
- Asthma Society, Ireland
- Parkinson Patiënten Vereniging, Netherlands
- Stichting Hoofd Hart en Vaten (SHHV), Netherlands
- MS Vereniging, Netherlands
- Nederlandse Vereniging voor Addison en Cushing patiënten,
Netherlands
- Astma och Allergi Förbundet, Sweden
- Swedish Diabetes Association, Sweden
- Riksförbundet Attention, Sweden
- Schweizerische Herzstiftung, Switzerland
Table 3 Patient organisations that did not respond to the
request to participate in the study
Non-responding patient organisations:
- Centrum ZitStil (ADHD), Belgium
- Association Parkinson, Belgium
- Diabetesforeningen, Denmark
- Asthma and Allergy Forbundet, Denmark
- Scleroseforeningen, Denmark
- ADHD-foreningen, Denmark
- Addison Foreningen, Denmark
- Diabetesliitto, Finland
- Suomen MS-liitto ry, Finland
- ADHD liitto ry, Finland
- Suomen Parkinson-liitto ry, Finland
- Addison Support group, Finland
- French Federation of Cardiology, France
- Association Française des Diabétiques, France
- Association Asthme & Allergies, France
- Lique Francaise contre la Sclérose en Plaques, France
- Association France Parkinson, France
- Association Surrenales, France
- Herzstiftung, Germany
- Deutsche Diabetes-Union, Germany
- German Allergy and Asthma Association (DAAP), Germany
- Deutsche Multiple Sklerose Gesellschaft (DMSG), Germany
- Bundesverband Arbeitskreis Überaktives Kind, Germany
- PARKINSonLINE e.v. (PAoL), Germany
- Netzwerk Hypophysen- und Nebennierenerkrankungen, Germany
- Irish Heart Foundation, Ireland
- Multiple Sclerose Society (MSI), Ireland
- The North Fingal ADD/ADHD Parent and Adult Support Group,
Ireland
- Diabetesvereniging, Netherlands
- Coalitie of Astmafonds, Vereniging Nederlands Davos &
Astmapatiënten, Netherlands
- Balans & Impuls, Netherlands
- Heart and Lung Association, Sweden
- Neurologiskt Handikappades Riksforbund (NHR), Sweden
- Parkinson Förbundet, Sweden
- Stödföreningen Hypophysis, Sweden
- Swiss Diabetes Society, Switzerland
- Coalition of aha! Zentrum für Allergie, Haut und Asthma,
Switzerland
- Schweizerische Multiple Sklerose Gesellschaft (SMSG), Switzerland
- Interessengruppe Aufmerksamkeitsdefizit-Syndrom, Switzerland
- Parkinson Schweiz, Switzerland
- British Heart Foundation, United Kingdom
- Diabetes UK, United Kingdom
- Asthma UK, United Kingdom
- MS Society, United Kingdom
- Thanet ADDers ADD/ADHD Support Group, United Kingdom
- Parkinson’s Disease Society, United Kingdom
- Addison’s Disease Self Help Group, United Kingdom/Ireland
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openness. Large, professionalized organisations had more
detailed policies, sometimes aimed at cooperation with
the industry. Consequently, patient organisations that
requested reimbursement had more detailed policies.
Five small-scale patient organisations, that did not start a
reimbursement procedure, had no policy at all. Reasons
for lacking a policy were not provided.
Discussion
This exploratory, small-scale study shows that the role
of European patient organisations in the reimbursement
process of medicines for the seven conditions we stu-
died was generally limited. Still, some patient organisa-
tions adopted a role in this process.
In general, only the larger patient organisations played
a part in the decision-making process regarding
Table 4 Comparison between patient organisations that either did or did not try to obtain reimbursement
Organisations that tried to obtain reimbursement
(N = 10)
Organisations that did not try to obtain reimbursement
(N = 11)
Patient organisation
(and number if >1)
Asthma (and Allergy)
Heart and vascular disease (3)
Parkinson disease
Diabetes (2)
ADHD
Multiple Scleroses
Asthma (and Allergy) (2)
Heart and vascular disease (2)
Parkinson disease (2)
Diabetes
ADHD
Multiple Scleroses
Addison and Cushing disease (2)
Countries Belgium, Denmark, Ireland, Finland, Netherlands,
Sweden
Belgium, Denmark, Ireland, France, Netherlands, Sweden
Switzerland
Average number of paid
employees
26 (range: 7-80) 5 (range: 0-17)
Average number of volunteers 200-500 (range: <200 - >500) < 200 (range: <200-500)
Average number of affiliated
patients
31.080 (range: 5.500 - 90.000) 9.805 (range: 850 -36.000)
Sort organisation
(and number if > 1)
1
Independent: 9
An umbrella for a number of smaller patient
organisations: 2
Part of a European network of patient organisations: 6
Part of an international network of patient
organisations: 6
Independent: 10
An umbrella for a number of smaller patient organisations:
2
Part of a European network of patient organisations: 6
Part of an international network of patient organisations: 2
1 There are more answers possible for one organisation. For example, an organisation can be part of a European and international network.
Table 5 Medication for which reimbursement was sought and actions of the patient organisation
Medication
2 Patient organisation Actions
Atorvastatin and rosuvastatin Heart Association, Finland (Special) reimbursement application directed to the concerned
authorities
Statins Diabetes Federation, Ireland - Lobbying the government (national and local level) for
complete reimbursement.
The Departement of Health and politicians were asked to support
the application
Methylfenidate Riksförbundet Attention, Sweden - Informing the media
- Broadcasting the names of individuals who needed the
medication
- Commissioning university research on the life conditions of
members.
Glargin and detemir Vlaamse Diabetes Vereniging, Belgium Providing scientific advice to the concerned Minister.
Asthma inhaling medication Astma och Allergi Förbundet, Sweden Letters to the concerned authorities.
Clopidrogel Stichting Hoofd Hart en Vaten (SHHV),
Netherlands
- Inviting the concerned parties around the table
- Informing the media
- Letters to the concerned authorities
Statins Heart Foundation, Denmark Letters to the concerned authorities.
Interferon-beta Nationale Multiple Sclerose Liga,
Belgium
Written protest to the Department of Health.
Combination of levodopa&carbidopa
(duodopa)
Parkinson Association, Belgium Letters to the concerned authorities.
Rasagilin Parkinson Patiënten Vereniging,
Netherlands
Letters to the concerned authorities.
2 We asked for the most recent medicine for which action was taken (January 2007). Some patient organisations have taken more actions than for the above
mentioned medicines, but they did not specify their actions for these medicines.
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acquire better accessibility of medicines for patients.
They called for total reimbursement for everyone or for
an enlargement of the patient groups for whom the
medicine is reimbursed. They lobbied regarding a variety
of medicines and conditions. Most organisations
restricted themselves to simple, one-off actions. Only a
few engaged in multiple actions. This study also showed
that all the patient organisations that adopted a role in
the reimbursement process did have policies on how to
cooperate with the pharmaceutical industry. The fact
that large patient organisations were more likely to take
action in relation to the reimbursement process implies
that a certain degree of organisation or professionaliza-
tion is necessary to take up any role. The influence of
the patient organisations might be more widespread if
they were to collaborate to achieve their aim. Patient
organisations seem not to be unaware of the potential
influence of the pharmaceutical industry on their auton-
omy, by explicitly stating their policies. However, these
policies were usually stated in general terms. It remains
to be seen whether such general terms provide enough
clarity to effectively sustain the independence of patient
organisations. Besides, previous research indicates that
only 18 percent of Dutch patient organisations have an
official policy for cooperation with the pharmaceutical
industry [13]. Many patient organisations (all across
Europe) do not disclose clear information about their
funding or competing interests [5,9]. According to the
Dutch ‘code of conduct for sponsorship’ patient organi-
sations should describe the sponsored activities in detail
(with full financial disclosure) as well as the rights and
obligations of all involved parties [15].
It should be noted that this study was exploratory, and
only twenty-one patient organisations participated
(response 31%). For two countries, England and Germany,
no respondents were found. In Germany, patient organisa-
tions have no formal role in the reimbursement process,
but in the United Kingdom they have [16]. Reasons for
not participating (and withdrawal from the research) were
not given. The reasons may have to do with a lack of time,
a negative attitude towards sponsorship by the pharma-
ceutical industry or the absence of any activities in this
domain. Besides, responses to web-based questionnaires
are in general lower than those to mail questionnaires
[17-19]. Moreover, we had to rely on self-reported answers
from one representative of the patient organisation. The
limited size of this study also restricted the depth of our
analyses. Differences between countries could not be stu-
died. In addition, we only included a selection of patient
organisations. Although we reassured to have a range of
different diseases, it is not known whether these organisa-
tions are representative for all diseases. Because of the
explorative character of this study, the low response rate
and the selection of patient organisations our findings can-
not be generalized and further research is needed. This is
all the more important because patient organisations will
become a more powerful force, and will aim to influence
decisions on budget-allocation in health care. The reim-
bursement process offers promising opportunities for
studying this development. A larger scale study could pro-
vide insight into the role of patient organisations in differ-
ent countries. The potentially multi-stranded relationship
of patient organisations with the pharmaceutical industry,
possibly leading to a loss of autonomy, should be consid-
ered in such a study.
Conclusion
T h er o l eo fp a t i e n to r g a n i s a t i o n si nt h ep r o c e s so f
obtaining reimbursement for medicines is varied but
seems limited. Only large and more professional organi-
sations seem to play an active role in this respect.
Nevertheless, it should be stressed that patient organisa-
tions have the potential to play an important part in the
reimbursement process, i.e. contribute to the debate
about reimbursement of medicines. As a result, organi-
sations should be aware of the importance of stating an
official, detailed and transparent policy regarding (coop-
eration with) the pharmaceutical industry.
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